

Molecular Haemato-Oncology Trial Schedule 2023 – 2024

Accredited Programmes	Trial issue	APR 23	MAY 23	JUN 23	JUL 23	AUG 23	SEP 23	OCT 23	NOV 23	DEC 23	JAN 24	FEB 24	MAR 24
<b>BCR::ABL1 and AML Translocation Identification</b>	3	X				X				X			
<b>BCR::ABL1 Kinase Domain Variant (Mutation) Status</b>	3			X				X				X	
<b>BCR::ABL1 Major Quantification</b>	3		X				X				X		
<b>BCR::ABL1 Minor Quantification</b>	3		X				X				X		
<b>BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia</b>	3	X			X					X			
<b>FLT3 Mutation Status</b>	3				X				X				X
<b>IG/TCR Clonality Status</b>	3	X				X				X			
<b>JAK2 p.Val617Phe (V617F) Mutation Status</b>	3			X				X				X	
<b>KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease</b>	3		X				X				X		
<b>NPM1 Mutation Status</b>	3				X				X				X
<b>Paediatric Acute Leukaemia Translocations</b>	3			X				X				X	
<b>Post-Stem Cell Transplant Chimerism Monitoring</b>	5		X		X			X		X		X	

Non-accredited Programmes	Trial Issue	APR 23	MAY 23	JUN 23	JUL 23	AUG 23	SEP 23	OCT 23	NOV 23	DEC 23	JAN 24	FEB 24	MAR 24
<b>Lymphoid Gene Panels<sup>1</sup></b>	2						X <sup>4</sup>						X <sup>5</sup>
<b>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia</b>	2		X						X				
<b>Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods</b>	2					X							X
<b>**NEW** Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods</b>	1								X				
<b>Myeloid Gene Panels<sup>2</sup></b>	2					X <sup>4</sup>						X <sup>5</sup>	
<b>Myeloproliferative Neoplasms Diagnostic Testing<sup>3</sup></b>	2			X							X		

1. Previously CLL Gene Panels; 2. Previously AML& MDS Gene Panels; 3. Previously MPN Gene Panels. 4. Includes educational variant interpretation; 5. Technical focus.  
Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments. No review required.  
Author(s): Stuart Scott  
Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS accredited proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.  
Page 1 of 1

Molecular Trial Schedule 2023-2024 - Version: 1.0. Index: Administration 790. Printed: 01-Dec-2022 16:14